(RTTNews) - Lexicon Pharmaceuticals (LXRX) announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial showed that once-daily dosing of sotagliflozin 400 mg improved time-in-range and several continuous glucose monitoring parameters, including glucose variability, in insulin-treated type 2 diabetes patients. Researchers observed positive trends with the once-daily dose of 200 mg.
Craig Granowitz, Lexicon's senior vice president and chief medical officer, said: "While we are not pursuing an indication to treat people with type 2 diabetes, this study adds to the body of evidence supporting the incremental value of inhibiting SGLT1."
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
